This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Aug 30;7(10):548.

doi: 10.1038/nrneph.2011.123.

Transplantation: Does switching to a CNI-free regimen reduce cancer risk?

Rebecca Ireland

PMID: 21878883
DOI: 10.1038/nrneph.2011.123

Comment

Transplantation: Does switching to a CNI-free regimen reduce cancer risk?

Rebecca Ireland. Nat Rev Nephrol. 2011.

. 2011 Aug 30;7(10):548.

doi: 10.1038/nrneph.2011.123.

Author

Rebecca Ireland

PMID: 21878883
DOI: 10.1038/nrneph.2011.123

No abstract available

PubMed Disclaimer

Comment on

Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES; Sirolimus CONVERT Trial Study Group. Alberú J, et al. Transplantation. 2011 Aug 15;92(3):303-10. doi: 10.1097/TP.0b013e3182247ae2. Transplantation. 2011. PMID: 21792049 Clinical Trial.

References

1. Nat Clin Pract Oncol. 2007 Aug;4(8):462-9 - PubMed
1. Transplantation. 2011 Aug 15;92(3):303-10 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.